Incidence of transient neurological symptoms following spinal anesthesia with hyperbaric mepivacaine 4 % and the use of 2 ml cerebrospinal fluid for barbotage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031420

Enrollment

200

Registered

2023-03-27

Start date

2016-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients operated in spinal anesthesia

Interventions

Group 1: Included are Patients who are operated in spinal anesthesia. We use 2 ml Mepivacaine 4 % hyperbaric diluted with the same volume of cerebrospinal fluid if the operation time is expected to be

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: scheduled operation in spinal anesthesia

Exclusion criteria

Exclusion criteria: age < 18 years neurological disease procedure performed as same day surgery

Design outcomes

Primary

Measure	Time frame
incidence of transient neurological symptoms within 4 days after spinal anesthesia compared between the groups treated with mepivacaine 4 % hyperbaric and bupivacaine 0,5 % isobaric. Ward rounds were performed on postoperative days 1 and 4. If Patients were discharged before day 4 an interview via phone was carried out.	—

Secondary

Measure	Time frame
incidence of post-punctural headache incidence of infections at the puncture site	—

Countries

Germany

Contacts

Public ContactPeter Neumann

Evangelisches Krankenhaus Göttingen Weende

neumann@ekweende.de0049 551 50341800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026